ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,867.60
-0.80%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.285
0.07%
Bitcoin
64,274.37
-0.01%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Insmed Inc (INSM) Quote

Insmed Inc

Insmed Inc (INSM)

Lyxor Asset Management Luxembourg SA
Lyxor Asset Management Luxembourg SA
25.81
0.54
(2.14%)
Closed April 25 4:00PM
Delayed by 15 minutes
25.81
0.00
(0.00%)
After Hours: 5:30PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
25.81
Bid
24.46
Ask
26.20
Volume
2,740,799
25.34 Day's Range 25.955
17.411 52 Week Range 32.00
Market Cap
3.828B
Previous Close
25.27
Open
25.58
Last Trade
48671
@
25.81
(formt)
Last Trade Time
Financial Volume
$ 70,331,268
VWAP
25.6609
Average Volume (3m)
1,747,338
Shares Outstanding
148,491,583
Dividend Yield
-
PE Ratio
-5.11
Earnings Per Share (EPS)
-5.05
Revenue
305.21M
Net Profit
-749.57M

About Insmed Inc

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as ... Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.insmed.com
Headquarters
Bridgewater, New Jersey, USA
Founded
1970
Insmed Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INSM. The last closing price for Insmed was $25.27. Over the last year, Insmed shares have traded in a share price range of $ 17.411 to $ 32.00.

Insmed currently has 148,491,583 shares outstanding. The market capitalization of Insmed is $3.83 billion. Insmed has a price to earnings ratio (PE ratio) of -5.11.

Insmed (INSM) Options Flow Summary

INSM Options Flow

Overall Flow

Bearish

Net Premium

-481k

Calls / Puts

0.00%

Buys / Sells

66.67%

OTM / ITM

25.00%

Sweeps Ratio

0.40%

INSM Latest News

More News

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., April 5, 2024 BRIDGEWATER, N.J., April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:...

April 05 2024
PR Newswire (US)

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference PR Newswire BRIDGEWATER, N.J., March 27, 2024 —Additional Data from...

March 27 2024
PR Newswire (US)

Form 8-K - Current report

March 11 2024
Edgar (US Regulatory)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., March 5, 2024 BRIDGEWATER, N.J., March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:...

March 05 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

February 29 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 29 2024
Edgar (US Regulatory)

Insmed To Present at Three March Conferences

Insmed To Present at Three March Conferences PR Newswire BRIDGEWATER, N.J., Feb. 29, 2024 BRIDGEWATER, N.J., Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global...

February 29 2024
PR Newswire (US)

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health PR Newswire BRIDGEWATER, N.J., Feb. 28, 2024 — New survey...

February 28 2024
PR Newswire (US)

Form 8-K - Current report

February 22 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

February 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.43-1.638719512226.2426.5423.525289036024.64473976CS
4-1.21-4.4781643227227.0228.7123.525208401626.2675091CS
12-3.08-10.661128418128.8929.9123.525174733827.12500973CS
260.451.7744479495325.363223.04166440527.14527585CS
527.540.961223375218.313217.411144102925.15088061CS
156-9.69-27.295774647935.536.9716.04121076423.75628493CS
260-5.78-18.29692940831.5945.4412.09113558524.77831294CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
AIREreAlpha Tech Corporation
$ 1.14
(88.74%)
35.42M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
LICNLichen China Limited
$ 0.94
(67.86%)
15.08M
AMSTAmesite Inc
$ 3.31
(65.50%)
70.3M
NCINeo Concept International Group Holdings Ltd
$ 2.33
(-75.47%)
8.33M
GCTKGlucoTrack Inc
$ 0.466
(-38.68%)
1.7M
ISUNiSun Inc
$ 0.0922
(-38.12%)
9.79M
VAXXVaxxinity Inc
$ 0.1326
(-33.70%)
4.95M
EVOEvotec SE
$ 5.2199
(-31.77%)
1.55M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.43
(182.34%)
220.51M
TSLATesla Inc
$ 162.13
(12.06%)
181.24M
SQQQProShares UltraPro Short QQQ
$ 11.81
(-0.84%)
148.21M
BOFBranchOut Food Inc
$ 2.0144
(72.17%)
107.44M
NKLANikola Corporation
$ 0.6206
(-2.31%)
80.82M

INSM Discussion

View Posts
north40000 north40000 4 years ago
New 52-week high today, $36.48, backed off since ~ 10:15 am.
👍️0
infamous infamous 4 years ago
lookin good
👍️0
ClayTrader ClayTrader 4 years ago
* * $INSM Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 4 years ago
* * $INSM Video Chart 02-03-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
FTR FTR 6 years ago
Blueyedcatch,
Are you still around?
Yesterday was a great day for insmed!

GLTU
FTR
👍️0
blueyedcatch blueyedcatch 6 years ago
Very exciting times for Insmed. Great data,,major expansion app potential,,Japan totally in the works,and ready to be submitted once the data is ready, and translated. KaChing. 300 a share is not a stretch by any means for Insm,going forward. Next years a big year.
👍️0
oxnous oxnous 7 years ago
Chart that

👍️0
oxnous oxnous 7 years ago
Thanks for the encouragement. I will wait for a pullback. Or for the RSI to get back down to 50 or so. If I miss it, so be it. It looks a bit top heavy to me right now. GLTU
👍️0
FTR FTR 7 years ago
Oxnous,
I just think you're in time.
Take you're time to do some dd.

You will find out this is going a lot higher..,

http://files.shareholder.com/downloads/INSMED/399897590x0x690054/37e9b63d-74e7-4892-965b-a0ea6fb7cccf/INSMED-IR-Deck.pdf

See slide 6-7

Approval is around the corner....
👍️0
oxnous oxnous 7 years ago
LooKS like I missed this one. GLTA
👍️0
blueyedcatch blueyedcatch 7 years ago
Ahh yes,,but Gottlieb is transforming the FDA to make approval or disapproval times much faster. The FDA wants Arikace approved and so does the CDC,and everyone who`ll benefit from the drug. We`re getting approved,IMO,and we`re just waiting for the FDA letter to go before the FDA panel for our majority yes vote. I really want to hear about Iplex,because that`s icing on the cake big time,and no one`s expecting anything out of it,so that news breaks and we run a bunch more. I`m with Pianoman and others of long term,on where the share price should get to after approval,but throw in iplex and we`re definitely over 100-125.
👍️0
oxnous oxnous 7 years ago
I will continue to monitor for news. I have been burned too many times by the FDA--FDA taking too long before eventual approval.

And the FDA NOT approving a drug.

But, that is why there is a potential high return. Because there definitely high risk.

GLTU
👍️0
blueyedcatch blueyedcatch 7 years ago
Iplex is free and clear for Insm from the settlement in October,next month.Not sure if it`s clear October 1st or the 31st.
👍️0
north40000 north40000 7 years ago
Been a long time. Was the drug involved there Iplex and the DNA patent one of Cabiily that evolved from an interference DNA lost in PTO but won in settlement in D.Ct.? That DNA/Roche patent should be about to expire, if it hasn't already expired.
👍️0
Reluctant Observer Reluctant Observer 7 years ago
Smart man.
👍️0
north40000 north40000 7 years ago
In since DNA patent battle that was settled....sold off a 1/3 of shares for LTCG in SEP-IRA, other 2/3 remain there
👍️0
Crazyjake27 Crazyjake27 7 years ago
PGA$. Worked good today for me :).
👍️0
John Kent John Kent 7 years ago
Knew this was pumped and would head down soon enough
👍️0
Crazyjake27 Crazyjake27 7 years ago
Thank you JK.
👍️0
FTR FTR 7 years ago
Blueyedcatch,
Sorry I don't have an account to post..
Just lurking...
👍️0
blueyedcatch blueyedcatch 7 years ago
Can you do us a favor and post a message over there and tell them to come over here? I`d like to hear what Pianoman is saying these days. Thanks in advance. Oh,don`t tell terry,we don`t want him over here.
👍️0
FTR FTR 7 years ago
Reluctant,
Welcome back...
I'm still here since 2001...

The other oldies are on InvestorVillage...

GLTY
👍️0
blueyedcatch blueyedcatch 7 years ago
I am. Since 2006
👍️0
Reluctant Observer Reluctant Observer 7 years ago
Anyone here from the "old days"?
2008 ish?
👍️0
blueyedcatch blueyedcatch 7 years ago
Wow that`s a lot of cash. More than enough extra to get Iplex going again. 377 million plus cash on hand,which is probably around 60 mln. They said 75 on the call,but that was for the end of June,so they`ve probably spent some of that 75 mln since,and that`s where I get the 60 mln. So a grand total of 430 mln minimum,and certainly a company in a position to start the new year off with super strength. Will Lewis has stated several times that he plans to turn Insmed into a stand alone big pharma,with multiple App`s for Arikace,and we`re hoping Iplex reborn,or another acquisition of a late stage drug,who knows. Point is the companies situated perfectly to achieve what Lewis declared he would do.Is it a ploy to sell Insm for the highest price possible?or is he really gonna do it?
👍️0
fireopal fireopal 7 years ago
Insmed Announces Closing of Public Offering - https://finance.yahoo.com/news/insmed-announces-closing-public-offering-200100479.html
👍️0
tfusari tfusari 7 years ago
INSM looks higher
👍️0
John Kent John Kent 7 years ago
not yet
👍️0
Crazyjake27 Crazyjake27 7 years ago
Thanks man. Did you take a look at $CLF$. Yet? Do you think it could reach $20 or higher in the next 2 years?
👍️0
John Kent John Kent 7 years ago
I am happy for you great work
👍️0
Crazyjake27 Crazyjake27 7 years ago
I'm out at. 30.25. From 24. Quick three day. 6k
👍️0
blueyedcatch blueyedcatch 7 years ago
I`m wondering how fast, with the new FDA under Gottleib,we will see approval,especially when the CDC wants what we have, as well as the FDA practically holding Insmeds hand through this whole thing. Everyone wants it approved,so it`s just a question of how long. IMO,the EU will get us done for sure,and the FDA should be a gimme considering everything. So how long? Shorts aren`t gonna get anything because approval could happen anytime now,and the offering set the bottom while we wait for it.
👍️0
John Kent John Kent 7 years ago
good luck hope it works for you
👍️0
Crazyjake27 Crazyjake27 7 years ago
Trailing stop man. Trying to make some money back I lost in GIG$. I'm up 7k. If my stop hits I will make 5k . Nothing is long term
👍️0
John Kent John Kent 7 years ago
this was pumped up to sell shares good luck holding this one
👍️0
Crazyjake27 Crazyjake27 7 years ago
After the offering they will have around 450 million in cash and they have 55 million in debt and burning around 38 million a quarter. I have a trailing stop on this one. :)
👍️0
Crazyjake27 Crazyjake27 7 years ago
There is no revenue yet but and approved by FDA yet but I would be careful shorting this jk. If approved watch this move up quickly . Of course very risky. I only own 1k shares. Got at $24. We will see.
👍️0
John Kent John Kent 7 years ago
Nonsense pure nonsense. Its not an FDA approval no revenue pump and dump. Shorting this POS
👍️0
Crazyjake27 Crazyjake27 7 years ago
Only around 12 millions shares. This is a game changer. If they can pull in 1.6 billion a year on this and give it a x15 multiple. =. That is a 24 billion market cap. That is a 366. 96 a share
👍️0
crudeoil24 crudeoil24 7 years ago
Plenty of working capital! INSM is a great $$$$$ opportunity.
👍️0
TheFinalCD TheFinalCD 7 years ago
I TRIED GETTING FILLED


THEY WOULDNT FILL ME, SO I GAVE UP LOL



Canceled Buy 1000 INSM Limit 29.69 -- 09/07/17 10:18:25 09/07/17



Canceled Buy 1000 INSM Limit 29.60 -- 09/07/17 10:18:16 09/07/17



Canceled Buy 1000 INSM Limit 29.50 -- 09/07/17 10:17:52 09/07/17
👍️0
BoilerRoom BoilerRoom 7 years ago
Heard we got news today
👍️0
blueyedcatch blueyedcatch 7 years ago
That`s a lot of cash for? IPLEX?
👍️0
crudeoil24 crudeoil24 7 years ago
Investors here are forward looking and loading INSM shares.
👍️0
crudeoil24 crudeoil24 7 years ago
$350M+ Wow! This company is in fantastic cash position going forward. With the high volume sessions this week, that cash could be raised in three hours. Smart management!
👍️0
blueyedcatch blueyedcatch 7 years ago
That`s right,,I talked to a bunch of big boys about it and they thought it would be 25.00 a share. I was hoping for 29.-29.50,but 28.50 is still big enough to wreck shorts by the way side. Any that are shorting here hoping for a pullback,are playin with fire. Upgrades with inflated price targets are certainly on the way.
👍️0
TheFinalCD TheFinalCD 7 years ago
$28.50 is higher than some thought http://ih.advfn.com/p.php?pid=nmona&article=75594881&symbol=INSM

👍️0
BoilerRoom BoilerRoom 7 years ago
INSM My price target $50.00+
👍️0
BoilerRoom BoilerRoom 7 years ago
Stand sad he missed the bottom... hehe
👍️0
FTR FTR 7 years ago
Good info:

https://www.google.nl/amp/s/www.fool.com/amp/investing/2017/09/05/heres-why-insmed-incorporated-is-skyrocketing.aspx
👍️0

Your Recent History

NASDAQ
INSM
Insmed
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved